Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy: Implications for Risk Assessment, Prevention and Treatment

Author： Chatzizisis Yiannis S.   Koskinas Konstantinos C.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.33, Iss.3, 2010-03, pp. : 171-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SLCO1B1 variants and increased risk of statin-induced myopathy

By  

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Statin-induced myopathy: minimize the risk and manage according to symptoms and creatine kinase levels

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 10, 2010-10 ,pp. : 21-23

Adis International

Access to resources Recommend Favorite

Statin-induced myopathy: a review and update

By Abd Thura T   Jacobson Terry A  

Expert Opinion on Drug Safety, Vol. 10, Iss. 3, 2011-05 ,pp. : 373-387

Informa Healthcare

Access to resources Recommend Favorite

Risk assessment with statin therapy

By listed n.l.n.  

International Journal of Pharmaceutical Medicine, Vol. 15, Iss. 5, 2001-10 ,pp. : 221-222

Adis International

Access to resources Recommend Favorite

Epidemiology of Risk Factors for Hypertension: Implications for Prevention and Therapy

By Kornitzer M.  

Drugs, Vol. 57, Iss. 5, 1999-05 ,pp. : 695-712

Adis International

Access to resources Recommend Favorite